Sigma Planning Corp Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX)

Sigma Planning Corp increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNXFree Report) by 17.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,210 shares of the biotechnology company’s stock after buying an additional 5,701 shares during the quarter. Sigma Planning Corp’s holdings in REGENXBIO were worth $401,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in RGNX. Harbor Capital Advisors Inc. grew its position in shares of REGENXBIO by 48.5% during the third quarter. Harbor Capital Advisors Inc. now owns 36,082 shares of the biotechnology company’s stock worth $379,000 after acquiring an additional 11,784 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in REGENXBIO by 13.1% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 151,715 shares of the biotechnology company’s stock valued at $1,591,000 after purchasing an additional 17,525 shares during the period. nVerses Capital LLC raised its holdings in shares of REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 2,200 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of REGENXBIO during the third quarter worth about $146,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on RGNX. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Chardan Capital restated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Tuesday, October 22nd. Raymond James reiterated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright upped their price objective on shares of REGENXBIO from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Barclays reduced their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.64.

Read Our Latest Research Report on RGNX

Insider Activity

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 13.13% of the company’s stock.

REGENXBIO Stock Down 13.6 %

Shares of NASDAQ RGNX opened at $9.63 on Friday. The stock has a market capitalization of $477.07 million, a price-to-earnings ratio of -1.91 and a beta of 1.23. REGENXBIO Inc. has a 52 week low of $8.53 and a 52 week high of $28.80. The firm has a 50-day moving average price of $10.50 and a 200 day moving average price of $12.31.

REGENXBIO Company Profile

(Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Featured Stories

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNXFree Report).

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.